Nigel James Parr

This inventor holds 19 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Glaxo Group Limited, Glaxosmithkline Intellectual Property Development Limited, Glaxogrouplimited. Active years: 2012-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nigel James Parr. Retrieved from https://idiyas.com/inventor/nigel-james-parr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 10)

% Patents Active = 63.2

CIPO Patents = 2

EPO Patents = 13 (Patent Applications = 16)

Average Co-Inventor Count = 6.7

ph-index = 4

Forward Citations = 128(Granted Patents)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

Years Active: 2012-2021

Loading Chart...

Areas of Expertise:

Compounds

Polymorphs

Salts

Indazole Derivatives

Influenza Treatment

Benzpyrazol Derivatives

PI3 Kinase Inhibitors

4-Oxadiazol-2-YL-Indazoles

CCR4 Receptor Antagonists

4-Carboxamide Indazole Derivatives

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10946025 - Compounds (2021-03-16),

2. 10624898 - Compounds (2020-04-21),

3. 10383879 - Compounds (2019-08-20),

4. 9353098 - Polymorphs and salts (2016-05-31),

5. 9326987 - Indazole derivatives for use in the treatment of influenza virus infection (2016-05-03),

6. 9102668 - Polymorphs and salts (2015-08-11),

7. 8993576 - [object Object] (2015-03-31),

8. 8765743 - Compounds (2014-07-01),

9. 8735390 - Polymorphs and salts (2014-05-27),

10. 8658635 - Benzpyrazol derivatives as inhibitors of PI3 kinases (2014-02-25),

11. 8609657 - Compounds (2013-12-17),

12. 8586590 - Compounds (2013-11-19),

13. 8586583 - Compounds (2013-11-19),

14. 8580797 - Compounds (2013-11-12),

15. 8575162 - Compounds (2013-11-05),

Title: The Innovative Journey of Nigel James Parr

Introduction: Nigel James Parr, a prominent inventor based in Stevenage, GB, has made significant contributions to the field of pharmaceuticals with his extensive portfolio of 19 patents. His work primarily focuses on the development of compounds that inhibit kinase activity, a crucial mechanism in various biological processes.

Latest Patents: Among his most recent innovations, Nigel has developed compounds directed towards formula (I) and their salts, specifically designed as inhibitors of PI3-kinase activity. This groundbreaking research holds potential implications for treating diseases linked to abnormal kinase activity.

Career Highlights: Throughout his career, Nigel has been associated with leading companies in the pharmaceutical industry, including GlaxoSmithKline Intellectual Property Development Limited and Glaxo Group Limited. His dedication to research and development has established him as a noteworthy figure in the innovation landscape.

Collaborations: Nigel has worked alongside talented colleagues such as Joelle Le and Julie Nicole Hamblin, contributing to a collaborative environment that fosters innovation and creativity in drug discovery and development.

Conclusion: Nigel James Parr's impressive record of patents and his commitment to advancing pharmaceutical science exemplify the vital role inventors play in shaping the future of medicine. His innovations in kinase inhibitors continue to pave the way for new therapeutic strategies, underscoring the importance of research and collaboration in driving progress in the industry.

Profile summary based on public USPTO records.